Cargando…
Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers
Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are a very aggressive type of cancer, for which prognostic factors are lacking. We analysed clinical and histomorphological prognostic markers of overall survival (OS), completed with a record of biological and haematological data of patient...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225444/ https://www.ncbi.nlm.nih.gov/pubmed/28074897 http://dx.doi.org/10.1038/srep40609 |
_version_ | 1782493507251863552 |
---|---|
author | Freis, Patricia Graillot, Emmanuelle Rousset, Pascal Hervieu, Valérie Chardon, Laurence Lombard-Bohas, Catherine Walter, Thomas |
author_facet | Freis, Patricia Graillot, Emmanuelle Rousset, Pascal Hervieu, Valérie Chardon, Laurence Lombard-Bohas, Catherine Walter, Thomas |
author_sort | Freis, Patricia |
collection | PubMed |
description | Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are a very aggressive type of cancer, for which prognostic factors are lacking. We analysed clinical and histomorphological prognostic markers of overall survival (OS), completed with a record of biological and haematological data of patients diagnosed between December 2002 and December 2015. The median OS was 16 months (95% CI 13.9–18.1). After univariate analysis, performance status (PS) ≥ 2 and stage IV were associated with a worse outcome (9 months and 14 months, respectively), as well as patients with lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) levels ≥ 2 ULN (9 months and 8 months, respectively). After multivariate analysis, LDH and AST levels were the only factors that remained significantly associated with better survival: HR 0.36 (p = 0.04) and 0.31 (p = 0.03), respectively. When patients had elevated LDH and AST levels, OS was 20 months, when they had high LDH or AST levels, 13 months and 8 months in the group with low LDH and AST levels (p < 0.001). Therefore, biological data appeared to be more relevant prognostic factors than usual factors described in other studies (PS, stage, and Ki-67). Considering LDH and AST levels at diagnosis could help physicians to predict survival and to stratify patients for clinical trials. |
format | Online Article Text |
id | pubmed-5225444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52254442017-01-17 Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers Freis, Patricia Graillot, Emmanuelle Rousset, Pascal Hervieu, Valérie Chardon, Laurence Lombard-Bohas, Catherine Walter, Thomas Sci Rep Article Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are a very aggressive type of cancer, for which prognostic factors are lacking. We analysed clinical and histomorphological prognostic markers of overall survival (OS), completed with a record of biological and haematological data of patients diagnosed between December 2002 and December 2015. The median OS was 16 months (95% CI 13.9–18.1). After univariate analysis, performance status (PS) ≥ 2 and stage IV were associated with a worse outcome (9 months and 14 months, respectively), as well as patients with lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) levels ≥ 2 ULN (9 months and 8 months, respectively). After multivariate analysis, LDH and AST levels were the only factors that remained significantly associated with better survival: HR 0.36 (p = 0.04) and 0.31 (p = 0.03), respectively. When patients had elevated LDH and AST levels, OS was 20 months, when they had high LDH or AST levels, 13 months and 8 months in the group with low LDH and AST levels (p < 0.001). Therefore, biological data appeared to be more relevant prognostic factors than usual factors described in other studies (PS, stage, and Ki-67). Considering LDH and AST levels at diagnosis could help physicians to predict survival and to stratify patients for clinical trials. Nature Publishing Group 2017-01-11 /pmc/articles/PMC5225444/ /pubmed/28074897 http://dx.doi.org/10.1038/srep40609 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Freis, Patricia Graillot, Emmanuelle Rousset, Pascal Hervieu, Valérie Chardon, Laurence Lombard-Bohas, Catherine Walter, Thomas Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
title | Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
title_full | Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
title_fullStr | Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
title_full_unstemmed | Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
title_short | Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
title_sort | prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225444/ https://www.ncbi.nlm.nih.gov/pubmed/28074897 http://dx.doi.org/10.1038/srep40609 |
work_keys_str_mv | AT freispatricia prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers AT graillotemmanuelle prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers AT roussetpascal prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers AT hervieuvalerie prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers AT chardonlaurence prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers AT lombardbohascatherine prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers AT walterthomas prognosticfactorsinneuroendocrinecarcinomabiologicalmarkersaremoreusefulthanhistomorphologicalmarkers |